Oruka Therapeutics, Inc. — Director's Dealing 2024

Jan 31, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2024-01-30

Reporting Person: Hove Anders D (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-30	Stock Option (right to buy)	$1.64	A	6000	Acquired	2034-01-30	Common Stock (6000)	Direct

Footnotes

F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.